All Medicines
Dr. Aditya Singh

Medically Reviewed By

Dr. Aditya Singh, MBBS, MD (Pharmacology)

Reg No: MCI-654321 • Verified Medical Reviewer

Antineoplastic agents

Truqap

(capivasertib)

Uses, side effects, dosage information & price range

AstraZeneca AB

About this medicine

Truqap is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, Truqap plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practice standards should be considered.

Key Information

Salt / Composition

capivasertib

Category

Antineoplastic agents

Manufacturer

AstraZeneca AB

Need a doctor's consultation?

Don't self-medicate. Consult a doctor before taking any medicine.

Medical Disclaimer

This information is for educational purposes only and is not a substitute for professional medical advice. Always consult your doctor or pharmacist before taking any medication. Prices are indicative and may vary. Do not start, stop, or change the dosage of any medicine without your doctor's approval.

Disclaimer:Content on this page is for informational purposes only. Do not consume prescription medication without a registered practitioner's direct oversight.